Scedosporium prolificans: An emerging pathogen in France?

Medical Mycology

Volumn 47, Issue 4, 2009, Pages 343-350

  Grenouillet, Frederic ^a,b   Botterel, Françoise ^c   Crouzet, Julien ^a   Larosa, Fabrice ^a   Hicheri, Yosr ^c   Forel, Jean Marie ^d   Helias, Philippe ^a   Ranque, Stephane ^e   Delhaes, Laurence ^f  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e TIMONE HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Active immunotherapy; Antifungal agents; Breakthrough infections; Emerging infectious diseases; Mold; Scedosporium prolificans

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; TACROLIMUS; TERBINAFINE; VORICONAZOLE;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; DISSEMINATED SCEDOSPORIOSIS; DRUG TREATMENT FAILURE; FATALITY; FUNGUS CULTURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LUNG ASPERGILLOSIS; LYMPHOCYTOMA; MALE; MYCOSIS; NEUTROPENIA; SCEDOSPORIUM; SCEDOSPORIUM PROLIFICANS; ANIMAL; FRANCE; IMMUNE DEFICIENCY; ISOLATION AND PURIFICATION; MICROBIOLOGY; REVIEW;

ASPERGILLUS; FUNGI; SCEDOSPORIUM PROLIFICANS;

ADULT; AGED; ANIMALS; FRANCE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MYCOSES; SCEDOSPORIUM;

EID: 67449108559     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802454761     Document Type: Conference Paper

References (43)

1. Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: Review of an emerging mycosis. Clin Infect Dis 2002; 34: 467-476.
2. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006; 162: 1-15.
3. Malloch D, Salkin IF. A new species of Scedosporium associated with osteomyelitis in human. Mycotaxon 1984; 21: 247-255.
4. Cooley L, Spelman D, Thursky K, Slavin M. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis 2007; 13: 1170-1177.
5. Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21: 157-197.
6. Delhaes L, Harun A, Chen SC, et al. Molecular typing of Australian Scedosporium isolates showing genetic variability and numerous S. aurantiacum. Emerg Infect Dis 2008; 14: 282-290.
7. Idigoras P, Perez-Trallero E, Pineiro L, et al. Disseminated infection and colonization by Scedosporium prolificans: A review of 18 cases, 1990-1999. Clin Infect Dis 2001; 32: E158-165.
8. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16: 607-612.
9. de Hoog GS, Marvin-Sikkema FD, Lahpoor GA, et al. Ecology and physiology of the emerging opportunistic fungi Pseudallescheria boydii and Scedosporium prolificans. Mycoses 1994; 37 71-78.
10. Wood GM, McCormack JG, Muir DB, et al. Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis 1992; 14: 1027-1033.
11. Steinbach WJ, Perfect JR. Scedosporium species infections and treatments. J Chemother 2003; 15 (Suppl. 2): 16-27.
12. Summerbell RC, Krajden S, Kane J. Potted plants in hospitals as reservoirs of pathogenic fungi. Mycopathologia 1989; 106: 13-22.
13. Rabodonirina M, Paulus S, Thevenet F, et al. Disseminated Scedosporium prolificans (S. inflatum) infection after single-lung transplantation. Clin Infect Dis 1994; 19: 138-142.
14. Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: Clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89-99.
15. Crouzet J, Grenouillet F, Larosa F, et al. Infections disséminées à Scedosporium prolificans. A propos de 2 cas et revue de la littérature. Med Mal Inf 2007; 37: S115.
16. Jackson N, Menon BS, Zarina W, Zawawi N, Naing NN. Why is acute leukemia more common in males? A possible sex-determined risk linked to the ABO blood group genes. Ann Hematol 1999; 78: 233-236.
17. Maertens J, Lagrou K, Deweerdt H, et al. Disseminated infection by Scedosporium prolificans: An emerging fatality among haematology patients. Case report and review. Ann Hematol 2000; 79: 340-344.
18. Toy EC, Rinaldi MG, Savitch CB, Leibovitch ER. Endocarditis and hip arthritis associated with Scedosporium inflatum. South Med J 1990; 83: 957-960.
19. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22: 111-113.
20. Berenguer J, Rodriguez-Tudela JL, Richard C, et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine (Baltimore) 1997; 76: 256-265.
21. Tong SY, Peleg AY, Yoong J, et al. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis 2007; 9: 241-243.
22. Whyte M, Irving H, O'Regan P, et al. Disseminated Scedosporium prolificans infection and survival of a child with acute lymphoblastic leukemia. Pediatr Infect Dis J 2005; 24: 375-377.
23. Gosbell IB, Toumasatos V, Yong J, et al. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003; 46: 233-236.
24. Li JY, Yong TY, Grove DI, Coates PT. Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient. Transpl Infect Dis 2008; 10: 63-65.
25. Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: Successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis 2007; 39: 87-90.
26. Simitsopoulou M, Gil-Lamaignere C, Avramidis N, et al. Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob Agents Chemother 2004; 48: 3801-3805.
27. Gil-Lamaignere C, Roilides E, Maloukou A, et al. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 2002; 50 1027-1030.
28. Gil-Lamaignere C, Roilides E, Mosquera J, Maloukou A, Walsh TJ. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002; 46: 2234-2237.
29. Gil-Lamaignere C, Winn RM, Simitsopoulou M, et al. Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: Comparison with Aspergillus spp. Med Mycol 2005; 43: 253-260.
30. Kelleher P, Goodsall A, Mulgirigama A, et al. Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J 2006; 27: 1307-1310.
31. Dignani MC, Rex JH, Chan KW, et al. Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer 2005; 104: 199-204.
32. Roilides E, Dignani MC, Anaissie EJ, Rex JH. The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Med Mycol 1998; 36 (Suppl. 1): 12-25.
33. Safdar A. Difficulties with fungal infections in acute myelogenous leukemia patients: Immune enhancement strategies. Oncologist 2007; 12 (Suppl. 2): 2-6.
34. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-921.
35. Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L, et al. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans Antimicrob Agents Chemother 2008; 52: 1136-1139.
36. Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47: 106-117.
37. Munoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with invasive fungal infections: Should a combination of antifungal drugs be used? Curr Opin Infect Dis 2006; 19: 365-370.
38. Capilla J, Yustes C, Mayayo E, et al. Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits. Antimicrob Agents Chemother 2003; 47: 1948-1951.
39. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008; 61 (Suppl. 1): i19-30.
40. Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007; 67: 1803-1812.
41. Tintelnot K, Kaben U, Just-Nübling G, Horre R. Scedosporium prolificans in Germany. Patients with deep infections or long lasting colonisation between 1993 and 2007 and characterisation of the clinical isolates. In: Proceedings of 2nd Meeting of the ECMM/ISHAM Working Group on "Pseudallescheria/Scedosporium Infections". Angers, France, 7-8 June 2007.
42. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743-746.
43. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.